269 related articles for article (PubMed ID: 7049385)
1. Anticipatory vomiting in women receiving cyclophosphamide, methotrexate, and 5-FU (CMF) adjuvant chemotherapy for breast carcinoma.
Wilcox PM; Fetting JH; Nettesheim KM; Abeloff MD
Cancer Treat Rep; 1982 Aug; 66(8):1601-4. PubMed ID: 7049385
[TBL] [Abstract][Full Text] [Related]
2. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
Hainsworth JD; Jolivet J; Birch R; Hopkins LG; Greco FA
Cancer; 1997 Feb; 79(4):740-8. PubMed ID: 9024712
[TBL] [Abstract][Full Text] [Related]
3. [Usefulness of ramosetron hydrochloride on nausea and vomiting in CMF or CEF therapy for breast cancer].
Taguchi T; Tsukamoto F; Watanabe T; Yoneda K; Takamura Y; Hojo S; Shiba E; Noguchi S
Gan To Kagaku Ryoho; 1999 Jul; 26(8):1163-70. PubMed ID: 10431583
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant chemotherapy (CMF) for breast carcinoma. Patient's compliance and total dose achieved.
Lee YT
Am J Clin Oncol; 1983 Feb; 6(1):25-30. PubMed ID: 6687656
[TBL] [Abstract][Full Text] [Related]
5. Concurrent cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy and radiotherapy for breast carcinoma: a well tolerated adjuvant regimen.
Isaac N; Panzarella T; Lau A; Mayers C; Kirkbride P; Tannock IF; Vallis KA
Cancer; 2002 Aug; 95(4):696-703. PubMed ID: 12209711
[TBL] [Abstract][Full Text] [Related]
6. [Incidence of emesis in outpatients on chemotherapy for breast cancer and the clinical efficacy of ondansetron hydrochloride tablets].
Ishida T; Kusaba T; Hayakawa H
Gan To Kagaku Ryoho; 2002 May; 29(5):723-8. PubMed ID: 12040676
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy-induced nausea, vomiting, and fatigue--the role of individual differences related to sensory perception and autonomic reactivity.
Zachariae R; Paulsen K; Mehlsen M; Jensen AB; Johansson A; von der Maase H
Psychother Psychosom; 2007; 76(6):376-84. PubMed ID: 17917474
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
Cocconi G; Di Blasio B; Boni C; Bisagni G; Ceci G; Rondini E; Bella M; Leonardi F; Savoldi L; Camisa R; Bruzzi P
Cancer; 2002 Jul; 95(2):228-35. PubMed ID: 12124820
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premonopausal patients with node-positive breast cancer: indirect comparison of dose and schedule in DBCG trials 77, 82, and 89.
Ejlertsen B; Mouridsen HT; Jensen MB
Acta Oncol; 2008; 47(4):662-71. PubMed ID: 18465334
[TBL] [Abstract][Full Text] [Related]
10. [Use of dexamethasone as an antiemetic in patients with breast cancer treated with the CMF regimen].
Domaradzka-Woźniak A; Wojtacki J; Dziewulska-Bokiniec A
Przegl Lek; 1994; 51(5):203-5. PubMed ID: 7938648
[TBL] [Abstract][Full Text] [Related]
11. Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate).
Schmid P; Untch M; Wallwiener D; Kossé V; Bondar G; Vassiljev L; Tarutinov V; Kienle E; Lüftner D; Possinger K;
Anticancer Res; 2002; 22(4):2325-32. PubMed ID: 12174922
[TBL] [Abstract][Full Text] [Related]
12. Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B.
Weiss RB; Woolf SH; Demakos E; Holland JF; Berry DA; Falkson G; Cirrincione CT; Robbins A; Bothun S; Henderson IC; Norton L;
J Clin Oncol; 2003 May; 21(9):1825-35. PubMed ID: 12721260
[TBL] [Abstract][Full Text] [Related]
13. [Clinical evaluation of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) on advanced and recurrent breast cancer. Clinical study group of CMF for breast cancer in Japan].
Nomura Y; Tominaga T; Adachi I; Koyama H; Fukami A
Gan To Kagaku Ryoho; 1994 Sep; 21(12):1949-56. PubMed ID: 8085846
[TBL] [Abstract][Full Text] [Related]
14. Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial.
Watanabe T; Sano M; Takashima S; Kitaya T; Tokuda Y; Yoshimoto M; Kohno N; Nakagami K; Iwata H; Shimozuma K; Sonoo H; Tsuda H; Sakamoto G; Ohashi Y
J Clin Oncol; 2009 Mar; 27(9):1368-74. PubMed ID: 19204202
[TBL] [Abstract][Full Text] [Related]
15. The standardised mistletoe extract PS76A2 improves QoL in patients with breast cancer receiving adjuvant CMF chemotherapy: a randomised, placebo-controlled, double-blind, multicentre clinical trial.
Semiglasov VF; Stepula VV; Dudov A; Lehmacher W; Mengs U
Anticancer Res; 2004; 24(2C):1293-302. PubMed ID: 15154663
[TBL] [Abstract][Full Text] [Related]
16. [Results of a study on fatigue in breast cancer patients receiving adjuvant chemotherapy: the first four days after treatment are the worst].
de Jong N; Kester AD; Schouten HC; Abu-Saad HH; Courtens AM
Pflege Z; 2007 Nov; 60(11):620-5. PubMed ID: 18062627
[TBL] [Abstract][Full Text] [Related]
17. Tastes associated with parenteral chemotherapy for breast cancer.
Fetting JH; Wilcox PM; Sheidler VR; Enterline JP; Donehower RC; Grochow LB
Cancer Treat Rep; 1985 Nov; 69(11):1249-51. PubMed ID: 3841501
[TBL] [Abstract][Full Text] [Related]
18. A comparison of patient-reported side effects among three chemotherapy regimens for breast cancer.
Greene D; Nail LM; Fieler VK; Dudgeon D; Jones LS
Cancer Pract; 1994; 2(1):57-62. PubMed ID: 8055007
[TBL] [Abstract][Full Text] [Related]
19. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J;
J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969
[TBL] [Abstract][Full Text] [Related]
20. Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled study.
Buser KS; Joss RA; Piquet D; Aapro MS; Cavalli F; Haefliger JM; Jungi WF; Bauer J; Obrist R; Brunner KW
Ann Oncol; 1993 Jun; 4(6):475-9. PubMed ID: 8353089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]